BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
232 results:

  • 1. Polycomb repressive complex 2 and its core component ezh2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
    Cheng Y; Song Z; Fang X; Tang Z
    Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The competitive mechanism of EZH1 and ezh2 in promoting oral squamous cell carcinoma.
    Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
    Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.
    Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
    Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Drug-induced inhibition of HMGA and ezh2 activity as a possible therapy for anaplastic thyroid carcinoma.
    De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
    Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 (ezh2)-dependent sirtuin-3 determines sensitivity to glucose starvation in radioresistant head and neck cancer cells.
    Chang HW; Park JJ; Lee WH; Kim SH; Lee JC; Nam HY; Kim MR; Han MW; Lee YS; Kim SY; Kim SW
    Cell Signal; 2024 Mar; 115():111029. PubMed ID: 38163576
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Enhanced Transcriptional Signature and Expression of Histone-Modifying Enzymes in Salivary Gland Tumors.
    Manou M; Loupis T; Vrachnos DM; Katsoulas N; Theocharis S; Kanakoglou DS; Basdra EK; Piperi C; Papavassiliou AG
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887281
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
    Craig S; Stretch C; Farshidfar F; Sheka D; Alabi N; Siddiqui A; Kopciuk K; Park YJ; Khalil M; Khan F; Harvey A; Bathe OF
    Front Endocrinol (Lausanne); 2023; 14():1220617. PubMed ID: 37772080
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.
    Yuan J; Liu H; Hu S; Miranda RN; Xu X; Bayerl MG; Artymiuk CJ; Berg H; King RL; Shi M; He R; Viswanatha D; Medeiros LJ; McPhail ED
    Hum Pathol; 2023 Nov; 141():22-29. PubMed ID: 37634651
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ezh2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway.
    Ding N; You A; Zhao S; Yang H; Lai C; Ye F
    Med Oncol; 2023 Aug; 40(10):281. PubMed ID: 37634215
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Brucea javanica oil inhibits tongue squamous cell invasion and metastasis by regulating miR-138-ezh2 pathway.
    Jiang L; Zhou J; Wu Y; Zhou L; Zhang C; Zhu J; Fang Z; Shao Y; Wang W
    J Stomatol Oral Maxillofac Surg; 2023 Dec; 124(6S):101611. PubMed ID: 37619672
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Yin Yang 1-Induced Long Noncoding RNA DUXAP9 Drives the Progression of Oral Squamous Cell Carcinoma by Blocking CDK1-Mediated ezh2 Degradation.
    Zhou W; Feng Y; Lin C; Chao CK; He Z; Zhao S; Xue J; Zhao XY; Cao W
    Adv Sci (Weinh); 2023 Sep; 10(25):e2207549. PubMed ID: 37401236
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Interplay between ezh2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
    Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
    Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Int Immunopharmacol; 2023 Aug; 121():110459. PubMed ID: 37307758
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Modulation of ezh2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid cancer.
    de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Circular RNA 0000311 Aggravates the Aggressiveness of Oral Squamous Cell Carcinoma via miR-876-5p/ezh2 Axis.
    Xu J; Lin Q; Zhao X
    J Environ Pathol Toxicol Oncol; 2023; 42(3):43-52. PubMed ID: 37017678
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via ezh2/STAT pathway.
    Tan R; Liu J; Wang J; Zhang W; He M; Zhang Y
    Sci Rep; 2023 Apr; 13(1):5363. PubMed ID: 37005451
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. ezh2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts cancer Transformation.
    Ganesh D; Dafar A; Niklasson J; Sandberg I; Braz-Silva P; Sapkota D; Öhman J; Giglio D; Hasséus B
    Anticancer Res; 2023 Apr; 43(4):1533-1542. PubMed ID: 36974822
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
    Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
    Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells.
    Zunitch MJ; Fisch AS; Lin B; Barrios-Camacho CM; Faquin WC; Tachie-Baffour Y; Louie JD; Jang W; Curry WT; Gray ST; Lin DT; Schwob JE; Holbrook EH
    Mod Pathol; 2023 May; 36(5):100122. PubMed ID: 36841178
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of ezh2.
    Duan Y; Yue K; Ye B; Chen P; Zhang J; He Q; Wu Y; Lai Q; Li H; Wu Y; Jing C; Wang X
    Cell Death Dis; 2023 Feb; 14(2):149. PubMed ID: 36813772
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.